NCT00317434View on ClinicalTrials.gov

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

April 30, 2007

Conditions
Ovarian Cancer
Interventions
DRUG

lapatinib

Trial Locations (2)

35205

University of Alabama at Birmingham, Birmingham

48202

Indiana University School of Medicine, Indianapolis

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Alabama at Birmingham

OTHER